Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MIST Milestone Pharmaceuticals Inc. daily Stock Chart
MIST [NASD]
Milestone Pharmaceuticals Inc.
Healthcare | Biotechnology | Canada
statements
Index- P/E- EPS (ttm)-1.95 Insider Own9.90% Shs Outstand23.89M Perf Week-2.24%
Market Cap489.98M Forward P/E- EPS next Y-2.84 Insider Trans23.68% Shs Float22.77M Perf Month-4.52%
Income-46.70M PEG- EPS next Q-0.52 Inst Own79.10% Short Float0.09% Perf Quarter10.15%
Sales- P/S- EPS this Y-186.70% Inst Trans9.30% Short Ratio0.49 Perf Half Y15.22%
Book/sh5.42 P/B3.78 EPS next Y5.00% ROA- Target Price29.63 Perf Year-
Cash/sh5.71 P/C3.59 EPS next 5Y- ROE- 52W Range12.36 - 27.95 Perf YTD28.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.62% Beta-
Dividend %- Quick Ratio16.00 Sales past 5Y- Gross Margin- 52W Low65.94% ATR1.29
Employees23 Current Ratio16.00 Sales Q/Q- Oper. Margin- RSI (14)50.84 Volatility4.00% 6.30%
OptionableNo Debt/Eq0.00 EPS Q/Q-117.40% Profit Margin- Rel Volume1.79 Prev Close21.43
ShortableYes LT Debt/Eq0.00 EarningsMar 04 Payout- Avg Volume41.66K Price20.51
Recom1.50 SMA20-4.42% SMA509.44% SMA2006.39% Volume74,407 Change-4.29%
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Jun-03-19Initiated Jefferies Buy $28
Jun-03-19Initiated Cowen Outperform $32
Feb-04-20 09:22AM  Here's Why We're Not Too Worried About Milestone Pharmaceuticals's (NASDAQ:MIST) Cash Burn Situation Simply Wall St.
Jan-15-20 07:00AM  Two Small Biotechs See Big Stock Purchases by Their Largest Holders Barrons.com
Dec-20-19 06:20PM  Should You Avoid Milestone Pharmaceuticals Inc. (MIST)? Insider Monkey
Nov-27-19 07:00AM  Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach CNW Group
Nov-14-19 07:00AM  Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Nov-13-19 07:00AM  Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update CNW Group
Oct-03-19 07:00AM  Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT CNW Group
Sep-10-19 07:00AM  Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development PR Newswire
07:00AM  Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development CNW Group
Aug-13-19 07:00AM  Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results CNW Group
Aug-08-19 11:39AM  Do Institutions Own Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST)? Simply Wall St.
Aug-06-19 07:00AM  Milestone Pharmaceuticals to Host Mid-Year Update Conference Call PR Newswire
07:00AM  Milestone Pharmaceuticals to Host Mid-Year Update Conference Call CNW Group
May-30-19 07:00AM  Milestone Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference CNW Group
May-21-19 04:05PM  Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting PR Newswire
04:05PM  Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting CNW Group
May-14-19 06:40PM  Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering CNW Group
May-13-19 04:05PM  Milestone Pharmaceuticals Announces Closing of Initial Public Offering CNW Group
May-08-19 11:02PM  Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering CNW Group
May-06-19 09:47AM  The Milestone Pharma IPO: What You Need To Know Benzinga
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker that has completed Phase II clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating atrial fibrillation and angina. The company was founded in 2003 and is headquartered in Montreal, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RTW INVESTMENTS, LP10% OwnerJan 13Buy16.25270,0004,387,5004,228,264Jan 13 05:07 PM
RTW INVESTMENTS, LP10% OwnerDec 31Buy15.5021,438332,3403,958,264Jan 02 04:26 PM
RTW INVESTMENTS, LP10% OwnerDec 30Buy15.481,33320,6383,936,826Jan 02 04:26 PM
Novo Holdings A/S10% OwnerNov 25Sale16.00240,0003,840,0002,434,470Nov 27 02:39 PM
RTW INVESTMENTS, LP10% OwnerNov 20Buy16.00400,0006,400,0003,935,493Nov 22 03:10 PM
open in yahoo | open in reuters | open in google